Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
GINA’s 2026 strategy keeps one message at the center: asthma treatment should include an inhaled corticosteroid (ICS), not rely on a short-acting bronchodilator alone. For most adults and adolescents, GINA prefers Track 1, using low-dose ICS-formoterol as the reliever at the first steps and as both daily maintenance and reliever therapy (MART) at higher steps. The substantial 2026 changes are more detailed acute-care pathways, revised oxygen thresholds and targets, more conservative short-acting beta2-agonist (SABA) dosing, and an option for ICS-formoterol in mild acute exacerbations managed by clinicians.
This is a framework for a conversation with your clinician, not a personal dosing plan. Licensing, available inhalers, local protocols, age, other illnesses and your previous response to treatment can all change the appropriate choice.
The 2026 edition at a glance
The latest edition identified here is the Global Initiative for Asthma (GINA) 2026 Global Strategy for Asthma Management and Prevention, published May 5, 2026. GINA’s 2026 Summary Guide followed in July. GINA says its scientific committee updates the strategy annually after reviewing new literature. The official report page is GINA’s 2026 Strategy Report, while the clinician-focused summary is available as a 2026 Summary Guide PDF.
For someone living with asthma, the practical message is continuity with more specific instructions for clinicians:
#1 Best Overall
- ICS-containing treatment remains the foundation for adults, adolescents and children aged 6–11.
- Adults and adolescents are generally directed toward Track 1, based on ICS-formoterol, when that option is licensed and suitable locally.
- Acute asthma assessment now has four clearer flowcharts covering adults and adolescents, children 6–11, and children aged 5 years and younger in primary-care and acute-care settings.
- Oxygen thresholds and targets have been revised, and recommended acute-care SABA doses are more conservative.
- Clinicians may use ICS-formoterol for mild exacerbations in adults, adolescents and children 6–11 presenting in primary care or an emergency department.
These changes guide supervised care. They do not tell a patient to start, stop or increase an inhaler without medical advice.
What specifically changed in 2026?
Four acute-asthma flowcharts
GINA’s 2026 changes overview adds four flowcharts for assessing and treating acute asthma. They distinguish adults and adolescents from children 6–11, and they include both primary-care and acute-care or emergency settings. Children aged 5 and younger have a separate pathway. The flowcharts are intended to standardize recognition of severity, initial treatment, reassessment and decisions about transfer or escalation.
For children, GINA emphasizes using a validated severity score rather than relying only on a single symptom or oxygen reading. The 2026 overview gives the Pediatric Respiratory Assessment Measure (PRAM) as an example. A score is a clinical tool; parents should not attempt to calculate one as a substitute for urgent assessment.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Epinephrine comes first when anaphylaxis is also present
If asthma-like breathing difficulty occurs with anaphylaxis, GINA’s 2026 overview says epinephrine should be given first. This reflects the danger of treating the wheeze while delaying the treatment that addresses life-threatening allergic shock. Anyone with suspected anaphylaxis needs emergency care and should follow their prescribed emergency plan.
New oxygen thresholds and targets
The identified 2026 flowcharts say supplemental oxygen is not recommended unless oxygen saturation is below 92%. When oxygen is used, the target range for adults, adolescents and children aged 6–11 is 92–95%. For children aged 5 and younger with acute wheeze or a severe exacerbation, the stated target when oxygen is used is at least 92%.
Those numbers are not a home-treatment algorithm. A pulse oximeter is only one piece of an assessment that also includes breathing effort, speech, alertness, airflow and response to treatment. GINA’s Summary Guide warns that pulse oximetry may overestimate saturation in people with hypoxemia and dark skin; altitude can also require target adjustment. A reading that appears acceptable does not rule out a dangerous attack.
More conservative SABA dosing
The 2026 overview describes more conservative recommended SABA doses in acute care because excessive dosing can cause toxicity, including lactic acidosis. Lactic acidosis can make a person breathe faster and may be mistaken for worsening bronchospasm, creating a cycle of unnecessary additional SABA. The dose and delivery method must therefore be selected and reassessed by a clinician.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →ICS-formoterol is an option for mild exacerbations under supervision
GINA now includes ICS-formoterol as an option for mild exacerbations in adults, adolescents and children aged 6–11 who present in primary care or an emergency department. This does not mean every reliever containing formoterol is interchangeable, or that a person should self-treat a severe attack with extra doses. The product’s approval, prescribed maximum, inhaler strength and local protocol matter.
The central routine-care change: ICS-containing treatment
GINA states that adults, adolescents and children aged 6–11 should receive treatment that includes an inhaled corticosteroid. ICS reduces airway inflammation, whereas a bronchodilator alone mainly eases airway narrowing for a limited time. The 2026 strategy therefore does not treat SABA-only reliance as the preferred routine approach.
Ask your clinician to identify which part of your regimen is the anti-inflammatory medicine, when to take it, and what to do if symptoms increase. Do not discontinue a controller because you feel well: good control can mean the treatment is preventing symptoms and exacerbations.
Adult and adolescent Track 1 versus Track 2
For people aged 12 and older, GINA presents two treatment tracks. Track 1 is preferred; Track 2 remains an alternative when ICS-formoterol is unavailable, not licensed for the relevant use, unsuitable for the individual, or not selected after clinical review.
| Feature | Track 1 (GINA preferred) | Track 2 (alternative) |
|---|---|---|
| Reliever | Low-dose ICS-formoterol, so the reliever contains an anti-inflammatory ICS | A different reliever/controller arrangement; the reliever is not the Track 1 ICS-formoterol approach |
| Maintenance and relief | At Steps 3–4, ICS-formoterol can be used as maintenance-and-reliever therapy (MART) | Maintenance and reliever medicines follow a separate arrangement |
| Why GINA prefers it | The guide says it reduces severe-exacerbation risk and is simpler | Used when Track 1 cannot be used or another plan is clinically preferred |
| Adherence implications | One reliever approach can reinforce delivery of ICS when symptoms occur; actual adherence still depends on the person and prescription | Success depends on taking the prescribed controller consistently as well as using the reliever correctly |
| Availability | Depends on national approval, product labeling, inhaler strength and supply | Also depends on local licensing and the clinician’s assessment |
“Preferred” does not mean universally appropriate. Formoterol-containing products differ, and not every inhaler labeled for relief is approved for MART. Your written plan should state the exact inhaler, maintenance schedule, symptom-relief instructions and maximum permitted use.
How the pathways differ by age
Age is not a minor detail in GINA’s strategy. The Summary Guide is focused on adults, adolescents and children aged 6–11; it directs readers to the full report for detailed recommendations for children aged 5 and younger.
| Age group | 2026 strategy emphasis | What to clarify with the clinician |
|---|---|---|
| Adults and adolescents (12+) | Track 1 is preferred, with low-dose ICS-formoterol as reliever at Steps 1–2 and MART at Steps 3–4 | Whether the prescribed product is licensed for the proposed use and what maximum daily use applies |
| Children 6–11 | Step 1 may use as-needed low-dose ICS-formoterol or an ICS-SABA option; higher steps include daily ICS-containing treatment | Technique, supervision, growth and side-effect monitoring, and whether Step 4 warrants pediatric asthma-expert review |
| Children 5 and younger | A separate acute-wheeze and exacerbation pathway; detailed routine recommendations require the full report | Age-appropriate diagnosis, delivery device, trigger pattern and when urgent assessment is needed |
A child who needs Step 4 treatment may warrant review by a pediatric asthma expert. That is a reason to arrange specialist input, not a reason to change a child’s medicine at home.
What this means at a routine asthma appointment
GINA’s management cycle looks beyond the prescription. Before stepping treatment up or down, clinicians should review several modifiable and personal factors.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- Describe current control. Bring the number of daytime symptoms, night waking, activity limits and reliever-use days. Mention any urgent visits, oral steroid courses or hospital care.
- Demonstrate inhaler technique. Ask the clinician or pharmacist to watch you use the exact device you carry. A correct prescription cannot work properly if the steps, breathing pattern or timing are wrong.
- Check adherence without blame. Explain missed doses, cost or supply problems, schedule difficulties, side effects and whether the device is hard to use. These details can change the safest solution.
- Review lung function and comorbidities. Results, nasal disease, reflux, obesity, anxiety, sleep problems and other conditions may affect symptoms or treatment response.
- Discuss exposures and goals. Tobacco smoke, vaping, air pollution and allergens can increase risk. Tell the clinician what activities you want to do and which treatment burdens matter to you.
- Update the written asthma action plan. It should explain daily treatment, signs of deterioration, the prescribed reliever steps and when to seek urgent help.
GINA’s framework treats preferences and goals as part of the decision, alongside exacerbation history, side effects, lung function, technique and adherence. A step change should follow that review rather than a single difficult day.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Does GINA still recommend a rescue inhaler?
Yes, people still need a prescribed reliever for symptom episodes, but GINA’s preferred adult and adolescent reliever in Track 1 is low-dose ICS-formoterol rather than a SABA-only approach. In Track 2, a different reliever arrangement is used with a separate controller. The word “rescue inhaler” therefore does not identify one medicine or one treatment track.
Carry and use the reliever exactly as written in your action plan. Needing it more often than expected, waking at night, limiting activities or receiving repeated urgent treatment signals the need for a clinical review. Do not respond by repeatedly escalating doses beyond the prescribed maximum.
Why the acute-care details matter
Asthma attacks can worsen quickly, and treatment decisions depend on severity and response. The 2026 flowcharts are designed to help clinicians reassess after initial therapy instead of assuming that persistent fast breathing always means more bronchospasm. SABA toxicity, infection, anaphylaxis, pneumothorax and other conditions can present with breathlessness or wheeze and require different treatment.
Recommended Free Tools
Seek emergency help for severe breathlessness, inability to speak normally, marked drowsiness or confusion, blue or gray lips, exhaustion, rapidly worsening symptoms or poor response to the prescribed action-plan steps. Do not delay emergency assessment to obtain a pulse-oximeter reading or to experiment with additional inhaler doses.
Common triggers and preventable risks
The 2026 Summary Guide continues to identify tobacco smoke, vaping, air pollution, allergens and inadequate ICS use as relevant exposures or risk factors. Reducing exposure can be part of asthma management, but trigger avoidance does not replace anti-inflammatory treatment when that treatment is prescribed.
Ask about vaccination, occupational exposures and conditions that mimic or worsen asthma. If symptoms occur mainly at work, around animals, during exercise or after a particular medicine, record the timing and bring it to the appointment rather than eliminating foods or activities without a clear reason.
The global context
GINA’s 2026 Summary Guide describes asthma as “a serious global health problem.” It reports that approximately 300 million people worldwide have asthma and that approximately 96% of people who die from asthma are in low-income or middle-income countries. Those figures are quoted as presented in the July 2026 guide; the surfaced passage does not identify the underlying estimate’s year or original study, so they should not be treated as a newly measured global census.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchThe disparity helps explain why GINA repeatedly qualifies recommendations by local availability, regulation and health-system resources. A strategy that is preferred in one country may not be licensed or reliably supplied in another.
How to use the 2026 strategy safely
- Use the date: the strategy and Summary Guide are 2026 documents, and GINA publishes annual updates.
- Check the exact product and label in your country; “ICS-formoterol” is a medicine class, not a single globally interchangeable inhaler.
- Keep a written action plan and make sure household members know when to call emergency services.
- Ask for a technique check whenever the device, spacer or formulation changes.
- Never use the revised oxygen thresholds or SABA discussion as a home dosing calculator.
- For a child under 6, ask specifically which age-appropriate pathway the clinician is following; do not extrapolate the 6–11 table.
GINA’s professional materials state that clinicians should use judgment and account for national regulations. The official program and publications are available through GINA’s program page and the 2026 Summary Guide publication page. The full 2026 report is written for healthcare professionals and policy-makers, so your own clinician remains the right person to translate it into an individual plan.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
